期刊文献+

甲异靛通过TLR4-TAK-NF-κB途径治疗银屑病的机制研究 被引量:2

Mechanism about therapeutic effect of meisoindigo on psoriasis via down-regulation of the TLR4-TAK-NF-κB pathways
原文传递
导出
摘要 在近年来的临床实践中发现,甲异靛对银屑病有很好的疗效,但作用机制不明。利用脂多糖刺激RAW264.7细胞后,发现甲异靛对其产生一氧化氮有明显的抑制作用。同时检测了甲异靛作用HaCaT细胞后对免疫相关细胞因子及上游通路细胞蛋白的影响。结果发现,甲异靛抑制了众多炎症相关因子的表达,如一氧化氮合成酶、环氧合酶2、肿瘤坏死因子等。对上游通路蛋白表达进行检测后发现,甲异靛可以相继抑制NF-κB、TAK和TLR4等蛋白的表达。本研究结果显示,甲异靛可以通过作用于TLR4-TAK-NF-κB通路,从而治疗或缓解银屑病。 Meisoindigo is an indigo natural derivative commonly used in anti-cancer therapy. In the clinical application, it was also found to have good therapeutic effect on psoriasis. In order to further understand its mechanism of action, human normal keratinocyte cell line HaCaT and RAW 264.7 were used to identify if meisoindigo could affect the inflammatory factors such as NO and other important cytokines which were highly involved in psoriasis. Our results indicated that meisoindigo decreased the production of NO in LPS-stimulated RAW 264.7 cells and reduced the expression of cytokines in LPS-stimulated HaCaT cells. And TLR4-TAK-NF-xB was a possible pathway mainly involved in the attenuation of iNOS and pro-inflammatory cytokine production by meisoindigo, which may take part in the therapeutic effect of meisoindigo on psoriasis.
出处 《药学学报》 CAS CSCD 北大核心 2013年第4期503-507,共5页 Acta Pharmaceutica Sinica
基金 国家自然科学青年科学基金资助项目(81001443) 医科院药物所基本科研业务费(2010CHX14)
关键词 甲异靛 银屑病 细胞因子 meisoindigo psoriasis cytokine
  • 相关文献

参考文献1

二级参考文献11

  • 1Tsankov N,Angelova I,Kazandjieva J.Drug-induced psoriasis.Recognition and management[J].Am J Clin Dermatol,2000,1:159-165.
  • 2Wolf R,Ruocco V.Triggered psoriasis[J].Adv Exp Med Biol,1999,455:221-225.
  • 3Ockenfels HM,Wagner SN,Keim-Maas C,et al.Lithium and psoriasis; cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium[J].Arch Dermatol Res,1996,8:173-178.
  • 4Asadullah K,Docke WD,Volk HD,et al.The pathophysiological role of cytokines in psoriasis[J].Drugs Today (Bare),1999,5:913-924.
  • 5Kapp A.The role of cytokines in the psoriatic inflammation[J].J Dermatol Sci,1993,5:133-142.
  • 6Weinberg JM,Bottino CJ,Lindholm J,et al.Biologic therapy for psoriasis; an update on the tumor necrosis factor inhibitors infliximab,etanercept,and adalimumab,and the T-cell-targeted therapies efalizumab and alefacept[J].J Drugs Dermatol,2005,4:544-555.
  • 7Wilmer JL,Luster MI.Chemical induction of interleukin8 a pro-inflammatory chemokine,in human epidermal keratinocyte cultures and its relation to cytogenetic toxicity[J].Cell Biol Toxicol,1995,11:37-50.
  • 8Gold MH,Holy AK,Roenigk HH Jr.Beta-blocking drugs and psoriasis.A review of cutaneous side effects and retrospective analysis of their effects on psoriasis[J].J Am Acad Dermatol,1988,19:837-841.
  • 9Yeung CK,Chan HH.Cutaneous adverse effects of lithium; epidemiology and management[J].Am J Clin Dermatol,2004,5:3-8.
  • 10Duan H,Koga T,Kohda F,et al.Interleukin-8-positive neutrophilis in psoriasis[J].J Dermatol Sci,2001,26:119-124.

共引文献6

同被引文献26

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部